SG&A at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s SG&A?
- Phathom Pharmaceuticals, Inc. (PHAT) reported SG&A of $54.01M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s SG&A decreased by 42.8% year-over-year, from $94.47M to $54.01M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Phathom Pharmaceuticals, Inc.'s SG&A has grown at a 40.4% compound annual growth rate (CAGR), from $101M to $279.72M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.